MedTrace Logo

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 430

Last updated 2023-10-02

No results posted yet for this study

Summary

The investigators hypothesize that the extent of sulfation of toxic BAs and their urinary elimination can be used as a biomarker to predict the severity and prognosis of hepatobiliary diseases. The investigators rationale in this project is that the discovery of biomarkers specific to liver injury would provide the foundation for a specific and non-invasive tool to evaluate disease prognosis, determine patients with higher risk of developing end-stage liver diseases, and determine patients with higher risk of recurrence of hepatobiliary complications after liver transplant.

Patients on the liver transplant list are continuously monitored during their hospitalization and are scheduled for follow-up visits for 12 months after their release post-surgery. Disease progression will be evaluated by monitoring MELD scores, survival, incidence of liver transplant, and incidence of complications related to hepatobiliary conditions such as fluid retention, GI bleeding, encephalopathy, and biliary stricture complications.

Conditions

  • Hepatobiliary Diseases

Sponsors & Collaborators

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Yazen M Alnouti, PhD · University of Nebraska

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2022-09-02
Completion
2022-09-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200082 on ClinicalTrials.gov